Scorpius Holdings, Inc. (SCPX)
NYSEAMERICAN: SCPX · Real-Time Price · USD
0.215
+0.012 (5.91%)
Feb 21, 2025, 4:00 PM EST - Market closed
Scorpius Holdings Revenue
Scorpius Holdings had revenue of $922.37K in the quarter ending September 30, 2024, with 27.55% growth. This brings the company's revenue in the last twelve months to $10.04M, up 351.08% year-over-year. In the year 2023, Scorpius Holdings had annual revenue of $6.99M with 1,789.60% growth.
Revenue (ttm)
$10.04M
Revenue Growth
+351.08%
P/S Ratio
0.04
Revenue / Employee
$119,575
Employees
84
Market Cap
1.05M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 6.99M | 6.62M | 1,789.60% |
| Dec 31, 2022 | 370.18K | -1.74M | -82.48% |
| Dec 31, 2021 | 2.11M | -835.16K | -28.33% |
| Dec 31, 2020 | 2.95M | -101.14K | -3.32% |
| Dec 31, 2019 | 3.05M | -2.74M | -47.37% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
SCPX News
- 4 weeks ago - Scorpius Holdings Announces Collaboration with KaloCyte to Advance Manufacturing for ErythroMer™ - GlobeNewsWire
- 5 weeks ago - Scorpius Holdings Cancels Planned Reverse Stock Split - GlobeNewsWire
- 5 weeks ago - Scorpius Holdings Announces Reverse Stock Split - GlobeNewsWire
- 3 months ago - Scorpius Holdings Launches Scorpius Ventures to Support U.S. Biotech Innovation through Flexible Equity-Based Onshoring Model - GlobeNewsWire
- 3 months ago - Scorpius Holdings Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability - GlobeNewsWire
- 3 months ago - Scorpius Holdings Announces Collaboration with Celltheon Corporation, a U.S.-Based Cell Line Development Company; First Client Signed Under New Partnership Agreement - GlobeNewsWire
- 4 months ago - Scorpius Holdings Announces Implementation of New Cost Savings Measures Expected to Save Over $2 Million Annually - GlobeNewsWire
- 5 months ago - Scorpius Selected for Rapid Response Partnership Vehicle (RRPV) to Accelerate Medical Countermeasure Development in Support of BARDA - GlobeNewsWire